Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication

Sanjay Rajagopalan, Jeffrey Trachtenberg, Emile Mohler, Jeffrey Olin, Scott McBride, Raphael Pak, Henrik Rasmussen, Ronald Crystal

Research output: Contribution to journalArticle

45 Citations (Scopus)


The long-term safety and efficacy of adenoviral delivery of growth factors in patients with peripheral arterial disease (PAD) is unknown. CI-1023 (AdGVVEGF121.10) is a replication-deficient adenovirus encoding human vascular endothelial growth factor isoform 121. In this phase I trial, we investigated the safety and efficacy of CI-1023 in subjects with advanced claudication symptoms secondary to infra-inguinal disease. Eighteen subjects >35 years of age with a median ankle brachial index (ABI) at rest of 0.525 (interquartile range 0.4) and angiographic disease involving the infra-inguinal vessels underwent intramuscular injection of CI-1023 (4 × 108 to 4 × 1010 particle units, n = 15) or placebo (n = 3). Eleven of 15 patients (73%) who received CI-1023 and 1 of 3 subjects (33%) who received placebo, completed 1 year of follow-up. Edema and rash were the most common early adverse event. One infra-inguinal bypass procedure occurred in each of the placebo and CI-1023 groups at days 29 and 104, respectively. One death (day 160) and 1 malignancy (day 274) occurred in the CI-1023 group. Conclusions on efficacy could not be made due to the small number of patients. However, there were encouraging trends in ABI at rest and peak walking time at follow-up.

Original languageEnglish
Pages (from-to)512-516
Number of pages5
JournalAmerican Journal of Cardiology
Issue number5
Publication statusPublished - 1 Sep 2002


ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this